http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 16:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Aura+Biosciences%2C+Inc.++++For%3A+Aug+05/26660410.html si-local-file:///var/storage/secattach/20260617/26660410.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Aura+Biosciences%2C+Inc.++++For%3A+Aug+05/26660410.html Wed, 17 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Aura+Biosciences%2C+Inc.++++For%3A+Aug+05/26660410.html si-local-file:///var/storage/secattach/20260617/26660410.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Aura+Biosciences%2C+Inc.++++For%3A+Aug+05/26660410.html Wed, 17 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aura+Biosciences%2C+Inc.+++++++++++++++++Filed+by%3A+Gibney+Anthony+S/26654554.html si-local-file:///var/storage/secattach/20260616/26654554.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aura+Biosciences%2C+Inc.+++++++++++++++++Filed+by%3A+Gibney+Anthony+S/26654554.html Tue, 16 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aura+Biosciences%2C+Inc.+++++++++++++++++Filed+by%3A+Gibney+Anthony+S/26654554.html si-local-file:///var/storage/secattach/20260616/26654554.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Aura+Biosciences%2C+Inc.+++++++++++++++++Filed+by%3A+Gibney+Anthony+S/26654554.html Tue, 16 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+16++Filed+by%3A+Gibney+Anthony+S/26654522.html si-local-file:///var/storage/secattach/20260616/26654522.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+16++Filed+by%3A+Gibney+Anthony+S/26654522.html Tue, 16 Jun 2026 16:30:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+16++Filed+by%3A+Gibney+Anthony+S/26654522.html si-local-file:///var/storage/secattach/20260616/26654522.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+16++Filed+by%3A+Gibney+Anthony+S/26654522.html Tue, 16 Jun 2026 16:30:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Johnson+David+Michael/26647876.html si-local-file:///var/storage/secattach/20260615/26647876.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Johnson+David+Michael/26647876.html Mon, 15 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Johnson+David+Michael/26647876.html si-local-file:///var/storage/secattach/20260615/26647876.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Johnson+David+Michael/26647876.html Mon, 15 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Srivastava+Sapna/26647885.html si-local-file:///var/storage/secattach/20260615/26647885.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Srivastava+Sapna/26647885.html Mon, 15 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Srivastava+Sapna/26647885.html si-local-file:///var/storage/secattach/20260615/26647885.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Srivastava+Sapna/26647885.html Mon, 15 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Bitetti+Teresa+Marie/26647894.html si-local-file:///var/storage/secattach/20260615/26647894.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Bitetti+Teresa+Marie/26647894.html Mon, 15 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Bitetti+Teresa+Marie/26647894.html si-local-file:///var/storage/secattach/20260615/26647894.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Bitetti+Teresa+Marie/26647894.html Mon, 15 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Mattessich+Antony+C./26647852.html si-local-file:///var/storage/secattach/20260615/26647852.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Mattessich+Antony+C./26647852.html Mon, 15 Jun 2026 16:30:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Mattessich+Antony+C./26647852.html si-local-file:///var/storage/secattach/20260615/26647852.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11++Filed+by%3A+Mattessich+Antony+C./26647852.html Mon, 15 Jun 2026 16:30:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11/26636215.html si-local-file:///var/storage/secattach/20260611/26636215.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11/26636215.html Thu, 11 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11/26636215.html si-local-file:///var/storage/secattach/20260611/26636215.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aura+Biosciences%2C+Inc.++++For%3A+Jun+11/26636215.html Thu, 11 Jun 2026 16:31:00 -0400 AURA O.07116383 http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661